{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:14:24Z","timestamp":1772021664313,"version":"3.50.1"},"reference-count":51,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,7,20]],"date-time":"2006-07-20T00:00:00Z","timestamp":1153353600000},"content-version":"vor","delay-in-days":7505,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[1986,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Various approaches to hormonal treatment of prostate carcinoma are discussed. Eighty\u2010one patients with prostatic carcinoma, eight with stage B, nine with stage C, and 64 with stage D disease, were treated subcutaneously daily for 3 months with the LH\u2010RH agonist D\u2010Trp\u20106\u2010LH\u2010RH (Decapeptyl) in order to evaluate the incidence of remissions according to WHO recommendations for oncologic trials. The findings were compared to those obtained with other hormonal therapies of prostatic carcinoma according to the statistical method of \u201cexpected response rate\u201d as adapted by Lee and Wesley for phase II trials. Treatment with D\u2010Trp\u20106\u2010LH\u2010RH greatly reduced serum LH and testosterone levels without raising serum prolactin. After 1\u20102 weeks of therapy, there was relief of subjective symptoms and a reversal of the signs of prostatism as well as a marked decrease in bone pain. At 90 days 52 patients had complete relief of prostatism and 21 had only mild signs and symptoms. Seventy paitents were experiencing no bone pain and an additional six had only mild pain. Prostatic size, evaluated by rectal examination and transabdominal ultrasonography, reverted to normal in 26.4% of patients (complete remission) and was reduced by more than 50% in an additional 17.6% (partial remission), the overall rate of complete plus partial regression of prostatic enlargement being 44%. Scans showed a major improvement of bone lesions in 14.8% of cases. This response increased to 37% after more than 6 months of follow\u2010up. Prostatic acid phosphatase levels were decreased by more than 50% in 61% of the patients, but this test appears to be a less valid marker than the lipid\u2010associated sialic acid (LASA). The increase in LASA before treatment and a reduction after treatment can frequently be correlated with the objective volume of the neoplasms. No flare\u2010up of the disease was encountered, and there were no side effects except for impotence. Statistical analyses of results by the method of Lee and Wesley indicated that the incidence of complete and partial regression (CR and PR) observed with D\u2010Trp\u20106\u2010LH\u2010RH was not significantly different from that recorded in previous studies for another LH\u2010RH analog, Buserelin. However, CR and PR obtained with D\u2010Trp\u20106\u2010LH\u2010RH (44%) were significantly higher than with subcapsular orchiectomy (22%). Hormonal effects and some other actions of D\u2010Trp\u20106\u2010LH\u2010RH were compared and contrasted with those produced by castration, estrogens, antiandrogens, and progestogens. The treatment of prostatic carcinoma with D\u2010Trp\u20106\u2010LH\u2010RH avoids the cardiovascular and mammotropic side effects of estrogens, hepatic effects of some antiandrogens, and psychological impact of orchiectomy. There is still no evidence that the combination of LH\u2010RH analogs and small doses of antiandrogens offers an advantage over the use of LH\u2010RH agonists alone. Our findings indicate that currently LH\u2010RH analogs may be the method of choice for the treatment of advanced prostatic carcinoma. We also suggest that hormonal therapy with LH\u2010RH agonists can be combined with chemotherapy, the intial response to which might be potentiated by an early and transitory increase in testosterone levels. Our results warrant continuation of large\u2010scale clinical trials with LHRH agonists to establish their long\u2010term efficacy.<\/jats:p>","DOI":"10.1002\/pros.2990090404","type":"journal-article","created":{"date-parts":[[2007,2,21]],"date-time":"2007-02-21T00:48:23Z","timestamp":1172018903000},"page":"327-342","source":"Crossref","is-referenced-by-count":23,"title":["Phase II trial with D\u2010Trp\u20106\u2010LH\u2010RH in prostatic carcinoma: Comparison with other hormonal agents"],"prefix":"10.1002","volume":"9","author":[{"given":"Georges","family":"Math\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leon","family":"Schwarzenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie L.","family":"Vovan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Machover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean L.","family":"Misset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Court","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Bouchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmond","family":"Pappo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew V.","family":"Schally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana M.","family":"Comaru\u2010Schally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland Y.","family":"Mauvernay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Duchier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Morin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Keiling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Kerbrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Achille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques C.","family":"Tronc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Metz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Prevot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,20]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-81621-5","volume-title":"Prostate Cancer","author":"Duncan W","year":"1981"},{"key":"e_1_2_1_3_2","volume-title":"Prostate Cancer","author":"Catalona WJ","year":"1984"},{"key":"e_1_2_1_4_2","first-page":"293","article-title":"Studies on prostatic cancer. I. The effect of castration on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins CS","year":"1941","journal-title":"Cancer Res"},{"key":"e_1_2_1_5_2","first-page":"229","article-title":"Prostatic cancer. UICC Technical Rep","volume":"48","author":"Coffey DS","year":"1979","journal-title":"Series"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"e_1_2_1_7_2","first-page":"286","article-title":"Etude comparative de fortes doses d'oestradiol\u201017\u2010\u03b2 administrees par voie percutanee et de l'orchiectomie bilaterale dans le traitement du cancer de la prostate","volume":"17","author":"Steg A","year":"1983","journal-title":"Ann Urol"},{"key":"e_1_2_1_8_2","first-page":"264","article-title":"Cancer of the prostate. Methods of evaluating new therapeutic modalities: Recent results of the NPCP. Prostate Cancer. UICC Technical Rep","volume":"48","author":"Horton J","year":"1979","journal-title":"Series"},{"key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0022-5347(17)64534-8","article-title":"Is subcapsular orchiectomy a definitive procedure? Studies of hormone excretion before and after orchiectomy","volume":"89","author":"O'Connor VJ","year":"1963","journal-title":"J Urol"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.0600117"},{"key":"e_1_2_1_11_2","first-page":"183","volume-title":"Role of Medroxyprogesterone in Endocrine\u2010Related Tumors","author":"Pavone\u2010Macaluso M","year":"1983"},{"key":"e_1_2_1_12_2","first-page":"34","article-title":"Comparison of various hormonal therapies for prostatic carcinoma","volume":"10","author":"Geller J","year":"1983","journal-title":"Semin Oncol"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.2930170409"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1981.tb03157.x"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(1984)54:4<744::AID-CNCR2820540426>3.0.CO;2-P"},{"key":"e_1_2_1_16_2","unstructured":"MussetM VovanML MatheG: Lipid bound sialic acid vs prostatic acid phosphatases as prostate cancer marker.Biomed Pharmacother(in press)."},{"key":"e_1_2_1_17_2","first-page":"267","article-title":"New hormonal therapy in prostatic carcinoma: Combined treatment with an LHRH agonists and an antiandrogen","volume":"5","author":"Labrie F","year":"1982","journal-title":"J Clin Invest Med"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.287.6407.1766"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0022-5347(17)51007-1","article-title":"Ketoconazole: A novel and rapid treatment for advanced prostatic cancer","volume":"130","author":"Trachtenberg J","year":"1983","journal-title":"J. Urol"},{"key":"e_1_2_1_20_2","volume-title":"Prosztata Rak","author":"Pinter J","year":"1983"},{"key":"e_1_2_1_21_2","first-page":"719","article-title":"Evaluation of aminoglutethimidine in stage D prostate cancer: An assessment of efficacy and toxicity in patients with tumor refractory to hormonal therapy","volume":"68","author":"Block M","year":"1984","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_22_2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF02934982","article-title":"Inhibition of the growth of some hormonedependent tumors by D\u2010Trp\u20106\u2010LH\u2010RH","volume":"1","author":"Schally AV","year":"1984","journal-title":"Med Oncol Tumor Pharmacother"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110320"},{"key":"e_1_2_1_24_2","first-page":"223","volume-title":"Actualites Cancerologiques, Entretiens de Bichat","author":"Mathe G","year":"1983"},{"key":"e_1_2_1_25_2","first-page":"1443","article-title":"Un analogue de la gonadoliberine dans le traitement des carcinomes prostatiques","volume":"13","author":"Mathe G","year":"1984","journal-title":"Nouv Presse Med"},{"key":"e_1_2_1_26_2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF02934983","article-title":"An oriented phase II trial of D\u2010Trp\u20106\u2010LH\u2010RH in patients with prostatic carcinoma","volume":"1","author":"Mathe G","year":"1984","journal-title":"Med Oncol Pharmacother"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(61)90060-1"},{"key":"e_1_2_1_28_2","unstructured":"MatheG Vo VanML: Echotomographic vs clinical rectal examination of local prostate cancer.Biomed Pharmacother(in press)."},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(84)90233-5"},{"key":"e_1_2_1_30_2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF02934985","article-title":"Advanced prostatic adenocarcinoma: Biological aspects and effects of androgen deprivation achieved by castration or agonistic analogues of LH\u2010RH Med Oncol","volume":"1","author":"Tolis G","year":"1984","journal-title":"Tumor Pharmacother"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)92279-6"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198411153112004"},{"key":"e_1_2_1_33_2","first-page":"403","article-title":"Statistical contributions to phase II trials in cancer: interpretation, analysis and design","volume":"8","author":"Lee YJ","year":"1981","journal-title":"Semin Oncol"},{"key":"e_1_2_1_34_2","first-page":"58","article-title":"Les essais phase II comparatifs de confirmation de l'hypothese nulle, Leur interet, notamment en oncologie","volume":"37","author":"Misset JL","year":"1983","journal-title":"Biomed Pharmacother"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)92488-7"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)92435-8"},{"key":"e_1_2_1_37_2","volume-title":"Therapeutic Trials in Oncology: Methods, Ethics and Results","author":"Arpaillange P"},{"key":"e_1_2_1_38_2","first-page":"425","article-title":"Considerations sur l'ethique des etudes phase II","volume":"38","author":"Dion S","year":"1984","journal-title":"Biomed Pharmacother"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.2990070104"},{"key":"e_1_2_1_40_2","first-page":"1011","article-title":"Treatment and survival of patients with cancer of the prostate","volume":"124","author":"Veterans Administration Cooperative Urological Research Group","year":"1967","journal-title":"Surg Gynecol Obstet"},{"key":"e_1_2_1_41_2","unstructured":"MatheGEnhancement of cytostatic effect by estrogens in castrated mouse mammary tumors.Biomed Pharmacother(submitted)."},{"key":"e_1_2_1_42_2","unstructured":"EdsmyrF EspostiPL AnderssonL NaslundI BlomgrenH:Clinical study on bestatin and pepleomycin in treatment of prostatic carcinoma. In Carter SK Ultmann J (eds): \u201cPepleomycin.\u201d Proc Int Cong Chemother Vienna August 28\u2010September 2 SY 87\u20132 1983 pp5\u20137."},{"key":"e_1_2_1_43_2","first-page":"1803","article-title":"Treatment of advanced colorectal and gastric adenocarcinomas with 5\u2010FU combined with high\u2010dose folinic acid: A pilot study","volume":"66","author":"Machover D","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_44_2","unstructured":"MatheG KidaniY: A new cytostatic platinum complex without renal toxicity: 1\u2010OHP.Cancer Lett(in press)."},{"key":"e_1_2_1_45_2","unstructured":"MatheG KidaniY: Phase I trial with dose intrapatient escalation of a new platinum complex 1\u2010OHP.Cancer Lett(in press)."},{"key":"e_1_2_1_46_2","unstructured":"MatheG UmezawaH OkaS MissetJL de VassalF MachoverD MussetM RibaudP TapieroH: An oriented phase II trial of THP\u2010adriamycin (ADM) in breast carcinoma: Similar effect to ADM without cardiotoxicity and less alopecia.Am J Clin Oncol(in press)."},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.32.1085"},{"key":"e_1_2_1_48_2","unstructured":"MissetJL MatheG Santeli GouveiaJ HomassonJP SudreMC GagetH. Regression of bronchial epidermoid metaplasia in heavy smokers with etretinate treatment.Cancer Detect Prevent(in press)."},{"key":"e_1_2_1_49_2","unstructured":"MatheG:Immunorestorators: Bestatin and tuftsin vs zine and thymulin vs. imuthiol. Paper presented at French\u2010Japanese Conference on Antibiotics in Tumor Pharmacology June 1985."},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(84)80036-1"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.250.21.2897"},{"key":"e_1_2_1_52_2","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jama.1984.03340310017012","article-title":"Radiation\u2010associated impotence","volume":"251","author":"Goldstein I","year":"1984","journal-title":"JAMA"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.2990090404","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.2990090404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T15:05:09Z","timestamp":1697814309000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.2990090404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1986,1]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1986,1]]}},"alternative-id":["10.1002\/pros.2990090404"],"URL":"https:\/\/doi.org\/10.1002\/pros.2990090404","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[1986,1]]}}}